Faculty Profiles

David Lovett, MD

4150 Clement St
San Francisco, CA 94121

A.B. Indiana University, Zoology and Chemistry, Highest Distinction
M.D. Indiana University, Highest Distinction
Resident in Internal Medicine, Yale University
Chief Resident in Internal Medicine, Yale University
Fellow in Nephrology, Yale University
Fellow, Alexander von Humboldt Stiftung, Medizinische Hochschule Hannover Germany
Clinical Activity: Professor of Medicine and Chief, Nephrology Section SFVAMC
University/Public Service: Principal Investigator UCSF T32 Academic Training Program in Nephrology 2006-2016
Member, UCSF Committee on Academic Personnel 2016-2017
Vice Chair, UCSF Committee on Academic Personnel 2017-2018

Scholarly Activity: Our laboratory has primarily focused in recent years on an examination of the role of matrix metalloproteinase 2 in progressive cardiac and renal failure. These studies have included determinations of transcriptional regulatory networks, impact of promoter haplotypes on gene expression and generation of a series of transgenic mice to directly test the significance of MMP-2 expression on renal and cardiac disease. We have demonstrated that MMP-2 alone is sufficient to trigger the entire process of progressive renal disease seen in humans, including glomerulosclerosis, tubular atrophy and interstitial fibrosis without the requirement for superimposed injury. In the heart we have published a series of studies demonstrating that MMP-2 directly mediates cardiomyocyte apoptosis and contractile failure. More recently we have characterized (Lovett, et al., PLoS One 2012) a novel intracelllular isoform of MMP-2 that activates innate immunity. The isoform is generated by oxidative stress mediated activation of an alternative promoter in the first intron of the MMP-2 gene, thereby generating an intracellular, active N-terminal truncated enzyme. Transgenic mice expressing this isoform in the heart develop severe cardiomyocyte hypertrophy, inflammation and sytolic failure. Transgenic mice expressing this isoform in the kidney develop progressive tubular atrophy due mitochondrial damage mediated regulated necrosis. We are currently determining the extent of expression of this MMP-2 isoform in clinical specimens of cardiac and renal tissue using a combination of histochemical and epigenetic approaches. In addition, we are studying the epigenetic regulation of the MMP-2 intronic promoter using a novel series of transgenic reporter mice and epigenetic techniques. We believe that both isoforms of MMP-2 represent appealing therapeutic targets and we are currently developing antibody and siRNA-based strategies to selectively inhibit the MMP-2 isoforms in models of cardiac and renal disease.

Awards and Honors

  American Society of Clinical Investigation

Related Web Sites

Recent Articles (124)

Spaulding K, Takaba K, Collins A, Faraji F, Wang G, Aguayo E, Ge L, Saloner D, Wallace AW, Baker AJ, Lovett DH, Ratcliffe MB. Short term doxycycline treatment induces sustained improvement in myocardial infarction border zone contractility. PLoS One. 2018; 13(2):e0192720.

Cowley PM, Wang GY, Joshi SK, Swigart PM, Lovett DH, Simpson PC, Baker AJ. a1A-Subtype Adrenergic Agonist Therapy for Failing Right Ventricle. Am J Physiol Heart Circ Physiol. 2017 Aug 19; ajpheart.00153.2017.

Baligand C, Qin H, True-Yasaki A, Gordon JW, von Morze C, Santos JD, Wilson DM, Raffai R, Cowley PM, Baker AJ, Kurhanewicz J, Lovett DH, Wang ZJ. Hyperpolarized 13 C magnetic resonance evaluation of renal ischemia reperfusion injury in a murine model. NMR Biomed. 2017 Oct; 30(10).

Landolt L, Eikrem Ø, Strauss P, Scherer A, Lovett DH, Beisland C, Finne K, Osman T, Ibrahim MM, Gausdal G, Ahmed L, Lorens JB, Thiery JP, Tan TZ, Sekulic M, Marti HP. Clear Cell Renal Cell Carcinoma is linked to Epithelial-to-Mesenchymal Transition and to Fibrosis. Physiol Rep. 2017 Jun; 5(11).

Ceron CS, Baligand C, Joshi S, Wanga S, Cowley PM, Walker JP, Song SH, Mahimkar R, Baker AJ, Raffai RL, Wang ZJ, Lovett DH. An intracellular matrix metalloproteinase-2 isoform induces tubular regulated necrosis: implications for acute kidney injury. Am J Physiol Renal Physiol. 2017 Jun 01; 312(6):F1166-F1183.

Kim SS, Shin N, Bae SS, Lee MY, Rhee H, Kim IY, Seong EY, Lee DW, Lee SB, Kwak IS, Lovett DH, Song SH. Enhanced expression of two discrete isoforms of matrix metalloproteinase-2 in experimental and human diabetic nephropathy. PLoS One. 2017; 12(2):e0171625.

Grubbs V, Garcia F, Jue BL, Vittinghoff E, Ryder M, Lovett D, Carrillo J, Offenbacher S, Ganz P, Bibbins-Domingo K, Powe NR. The Kidney and Periodontal Disease (KAPD) study: A pilot randomized controlled trial testing the effect of non-surgical periodontal therapy on chronic kidney disease. Contemp Clin Trials. 2017 Feb; 53:143-150.

Luk FS, Kim RY, Li K, Ching D, Wong DK, Joshi SK, Imhof I, Honbo N, Hoover H, Zhu BQ, Lovett DH, Karliner JS, Raffai RL. Immunosuppression With FTY720 Reverses Cardiac Dysfunction in Hypomorphic ApoE Mice Deficient in SR-BI Expression That Survive Myocardial Infarction Caused by Coronary Atherosclerosis. J Cardiovasc Pharmacol. 2016 Jan; 67(1):47-56.

Wanga S, Ceron CS, Delgado C, Joshi SK, Spaulding K, Walker JP, Song S, Olson JL, Lovett DH. Two Distinct Isoforms of Matrix Metalloproteinase-2 Are Associated with Human Delayed Kidney Graft Function. PLoS One. 2015; 10(9):e0136276.

Joshi SK, Lee L, Lovett DH, Kang H, Kim HT, Delgado C, Liu X. Novel intracellular N-terminal truncated matrix metalloproteinase-2 isoform in skeletal muscle ischemia-reperfusion injury. J Orthop Res. 2016 Mar; 34(3):502-9.

Cowley PM, Wang G, Chang AN, Makwana O, Swigart PM, Lovett DH, Stull JT, Simpson PC, Baker AJ. The a1A-adrenergic receptor subtype mediates increased contraction of failing right ventricular myocardium. Am J Physiol Heart Circ Physiol. 2015 Sep; 309(5):H888-96.

Alam SG, Lovett D, Kim DI, Roux KJ, Dickinson RB, Lele TP. The nucleus is an intracellular propagator of tensile forces in NIH 3T3 fibroblasts. J Cell Sci. 2015 May 15; 128(10):1901-11.

Zhang Q, Joshi SK, Lovett DH, Zhang B, Bodine S, Kim HT, Liu X. Matrix metalloproteinase-2 plays a critical role in overload induced skeletal muscle hypertrophy. Muscles Ligaments Tendons J. 2014 Oct-Dec; 4(4):446-54.

Ikizler TA, Lovett DH, Chertow GM, Mitch WE, Schiller B. Navigating toward research success in times of uncertainty: funding opportunities for early career investigators in nephrology. Am J Kidney Dis. 2015 Mar; 65(3):381-3.

Zhang Q, Joshi SK, Lovett DH, Zhang B, Bodine S, Kim H, Liu X. Matrix metalloproteinase-2 plays a critical role in overload induced skeletal muscle hypertrophy. Muscles Ligaments Tendons J. 2014 Jul; 4(3):362-70.

Lovett DH, Chu C, Wang G, Ratcliffe MB, Baker AJ. A N-terminal truncated intracellular isoform of matrix metalloproteinase-2 impairs contractility of mouse myocardium. Front Physiol. 2014; 5:363.

Shimkunas R, Makwana O, Spaulding K, Bazargan M, Khazalpour M, Takaba K, Soleimani M, Myagmar BE, Lovett DH, Simpson PC, Ratcliffe MB, Baker AJ. Myofilament dysfunction contributes to impaired myocardial contraction in the infarct border zone. Am J Physiol Heart Circ Physiol. 2014 Oct 15; 307(8):H1150-8.

Walker JP, Hiramoto JS, Gasper WJ, Auyang P, Conte MS, Rapp JH, Lovett DH, Owens CD. Vitamin D deficiency is associated with mortality and adverse vascular access outcomes in patients with end-stage renal disease. J Vasc Surg. 2014 Jul; 60(1):176-83.

Lovett DH, Mahimkar R, Raffai RL, Cape L, Zhu BQ, Jin ZQ, Baker AJ, Karliner JS. N-terminal truncated intracellular matrix metalloproteinase-2 induces cardiomyocyte hypertrophy, inflammation and systolic heart failure. PLoS One. 2013; 8(7):e68154.

Zhang Q, Joshi SK, Manzano G, Lovett DH, Kim HT, Liu X. Original article Muscle extracellular matrix degradation and contractibility following tendon rupture and disuse. Muscles Ligaments Tendons J. 2013 Jan; 3(1):35-41.

Chu C, Thai K, Park KW, Wang P, Makwana O, Lovett DH, Simpson PC, Baker AJ. Intraventricular and interventricular cellular heterogeneity of inotropic responses to a(1)-adrenergic stimulation. Am J Physiol Heart Circ Physiol. 2013 Apr 01; 304(7):H946-53.

Joshi SK, Liu X, Samagh SP, Lovett DH, Bodine SC, Kim HT, Feeley BT. mTOR regulates fatty infiltration through SREBP-1 and PPAR? after a combined massive rotator cuff tear and suprascapular nerve injury in rats. J Orthop Res. 2013 May; 31(5):724-30.

Chintala H, Liu H, Parmar R, Kamalska M, Kim YJ, Lovett D, Grant MB, Chaqour B. Connective tissue growth factor regulates retinal neovascularization through p53 protein-dependent transactivation of the matrix metalloproteinase (MMP)-2 gene. J Biol Chem. 2012 Nov 23; 287(48):40570-85.

Lovett DH, Mahimkar R, Raffai RL, Cape L, Maklashina E, Cecchini G, Karliner JS. A novel intracellular isoform of matrix metalloproteinase-2 induced by oxidative stress activates innate immunity. PLoS One. 2012; 7(4):e34177.

Teerlink JR, Iragui VJ, Mohr JP, Carson PE, Hauptman PJ, Lovett DH, Miller AB, Piña IL, Thomson S, Varosy PD, Zile MR, Cleland JG, Givertz MM, Metra M, Ponikowski P, Voors AA, Davison BA, Cotter G, Wolko D, Delucca P, Salerno CM, Mansoor GA, Dittrich H, O'Connor CM, Massie BM. The safety of an adenosine A(1)-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT. Drug Saf. 2012 Mar 01; 35(3):233-44.

Liu X, Joshi SK, Samagh SP, Dang YX, Laron D, Lovett DH, Bodine SC, Kim HT, Feeley BT. Evaluation of Akt/mTOR activity in muscle atrophy after rotator cuff tears in a rat model. J Orthop Res. 2012 Sep; 30(9):1440-6.

Mahimkar R, Alfonso-Jaume MA, Cape LM, Dahiya R, Lovett DH. Graded activation of the MEK1/MT1-MMP axis determines renal epithelial cell tumor phenotype. Carcinogenesis. 2011 Dec; 32(12):1806-14.

Findeisen HM, Gizard F, Zhao Y, Cohn D, Heywood EB, Jones KL, Lovett DH, Howatt DA, Daugherty A, Bruemmer D. Telomerase deficiency in bone marrow-derived cells attenuates angiotensin II-induced abdominal aortic aneurysm formation. Arterioscler Thromb Vasc Biol. 2011 Feb; 31(2):253-60.

Dahi S, Karliner JS, Sarkar R, Lovett DH. Transgenic expression of matrix metalloproteinase-2 induces coronary artery ectasia. Int J Exp Pathol. 2011 Feb; 92(1):50-6.

Lovett DH, Cheng S, Cape L, Pollock AS, Mertens PR. YB-1 alters MT1-MMP trafficking and stimulates MCF-7 breast tumor invasion and metastasis. Biochem Biophys Res Commun. 2010 Jul 30; 398(3):482-8.

Liu X, Manzano G, Lovett DH, Kim HT. Role of AP-1 and RE-1 binding sites in matrix metalloproteinase-2 transcriptional regulation in skeletal muscle atrophy. Biochem Biophys Res Commun. 2010 May 28; 396(2):219-23.

Goldman S, Lovett DH, Shalev E. Mechanisms of matrix metalloproteinase-2 (mmp-2) transcriptional repression by progesterone in jar choriocarcinoma cells. Reprod Biol Endocrinol. 2009 May 09; 7:41.

Mahimkar R, Nguyen A, Mann M, Yeh CC, Zhu BQ, Karliner JS, Lovett DH. Cardiac transgenic matrix metalloproteinase-2 expression induces myxomatous valve degeneration: a potential model of mitral valve prolapse disease. Cardiovasc Pathol. 2009 Sep-Oct; 18(5):253-61.

Wetmore JB, Lovett DH, Hung AM, Cook-Wiens G, Mahnken JD, Sen S, Johansen KL. Associations of interleukin-6, C-reactive protein and serum amyloid A with mortality in haemodialysis patients. Nephrology (Carlton). 2008 Oct; 13(7):593-600.

Dang AB, Tay BK, Kim HT, Nauth A, Alfonso-Jaume MA, Lovett DH. Inhibition of MMP2/MMP9 after spinal cord trauma reduces apoptosis. Spine (Phila Pa 1976). 2008 Aug 01; 33(17):E576-9.

McCloskey DT, Turcato S, Wang GY, Turnbull L, Zhu BQ, Bambino T, Nguyen AP, Lovett DH, Nissenson RA, Karliner JS, Baker AJ. Expression of a Gi-coupled receptor in the heart causes impaired Ca2+ handling, myofilament injury, and dilated cardiomyopathy. Am J Physiol Heart Circ Physiol. 2008 Jan; 294(1):H205-12.

Zhou HZ, Ma X, Gray MO, Zhu BQ, Nguyen AP, Baker AJ, Simonis U, Cecchini G, Lovett DH, Karliner JS. Transgenic MMP-2 expression induces latent cardiac mitochondrial dysfunction. Biochem Biophys Res Commun. 2007 Jun 22; 358(1):189-95.

Jansen PL, Rosch R, Jansen M, Binnebösel M, Junge K, Alfonso-Jaume A, Klinge U, Lovett DH, Mertens PR. Regulation of MMP-2 gene transcription in dermal wounds. J Invest Dermatol. 2007 Jul; 127(7):1762-7.

Jansen PL, Kever M, Rosch R, Krott E, Jansen M, Alfonso-Jaume A, Dooley S, Klinge U, Lovett DH, Mertens PR. Polymeric meshes induce zonal regulation of matrix metalloproteinase-2 gene expression by macrophages and fibroblasts. FASEB J. 2007 Apr; 21(4):1047-57.

Bergman MR, Teerlink JR, Mahimkar R, Li L, Zhu BQ, Nguyen A, Dahi S, Karliner JS, Lovett DH. Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction. Am J Physiol Heart Circ Physiol. 2007 Apr; 292(4):H1847-60.

Cheng S, Pollock AS, Mahimkar R, Olson JL, Lovett DH. Matrix metalloproteinase 2 and basement membrane integrity: a unifying mechanism for progressive renal injury. FASEB J. 2006 Sep; 20(11):1898-900.

Wetmore JB, Johansen KL, Sen S, Hung AM, Lovett DH. An angiotensin converting enzyme haplotype predicts survival in patients with end stage renal disease. Hum Genet. 2006 Sep; 120(2):201-10.

Mukherjee R, Mingoia JT, Bruce JA, Austin JS, Stroud RE, Escobar GP, McClister DM, Allen CM, Alfonso-Jaume MA, Fini ME, Lovett DH, Spinale FG. Selective spatiotemporal induction of matrix metalloproteinase-2 and matrix metalloproteinase-9 transcription after myocardial infarction. Am J Physiol Heart Circ Physiol. 2006 Nov; 291(5):H2216-28.

Alfonso-Jaume MA, Bergman MR, Mahimkar R, Cheng S, Jin ZQ, Karliner JS, Lovett DH. Cardiac ischemia-reperfusion injury induces matrix metalloproteinase-2 expression through the AP-1 components FosB and JunB. Am J Physiol Heart Circ Physiol. 2006 Oct; 291(4):H1838-46.

Lee JG, Dahi S, Mahimkar R, Tulloch NL, Alfonso-Jaume MA, Lovett DH, Sarkar R. Intronic regulation of matrix metalloproteinase-2 revealed by in vivo transcriptional analysis in ischemia. Proc Natl Acad Sci U S A. 2005 Nov 08; 102(45):16345-50.

Wang GY, Bergman MR, Nguyen AP, Turcato S, Swigart PM, Rodrigo MC, Simpson PC, Karliner JS, Lovett DH, Baker AJ. Cardiac transgenic matrix metalloproteinase-2 expression directly induces impaired contractility. Cardiovasc Res. 2006 Feb 15; 69(3):688-96.

Dahi S, Lee JG, Lovett DH, Sarkar R. Differential transcriptional activation of matrix metalloproteinase-2 and membrane type-1 matrix metalloproteinase by experimental deep venous thrombosis and thrombin. J Vasc Surg. 2005 Sep; 42(3):539-45.

Wetmore JB, Hung AM, Lovett DH, Sen S, Quershy O, Johansen KL. Interleukin-1 gene cluster polymorphisms predict risk of ESRD. Kidney Int. 2005 Jul; 68(1):278-84.

Parsa A, Lovett DH, Peden EA, Zhu L, Seldin MF, Criswell LA. Renin-angiotensin system gene polymorphisms predict the progression to renal insufficiency among Asians with lupus nephritis. Genes Immun. 2005 May; 6(3):217-24.

Mahimkar RM, Visaya O, Pollock AS, Lovett DH. The disintegrin domain of ADAM9: a ligand for multiple beta1 renal integrins. Biochem J. 2005 Jan 15; 385(Pt 2):461-8.

En-Nia A, Yilmaz E, Klinge U, Lovett DH, Stefanidis I, Mertens PR. Transcription factor YB-1 mediates DNA polymerase alpha gene expression. J Biol Chem. 2005 Mar 04; 280(9):7702-11.

Alfonso-Jaume MA, Mahimkar R, Lovett DH. Co-operative interactions between NFAT (nuclear factor of activated T cells) c1 and the zinc finger transcription factors Sp1/Sp3 and Egr-1 regulate MT1-MMP (membrane type 1 matrix metalloproteinase) transcription by glomerular mesangial cells. Biochem J. 2004 Jun 15; 380(Pt 3):735-47.

Cheng S, Lovett DH. Gelatinase A (MMP-2) is necessary and sufficient for renal tubular cell epithelial-mesenchymal transformation. Am J Pathol. 2003 Jun; 162(6):1937-49.

Harendza S, Lovett DH, Panzer U, Lukacs Z, Kuhnl P, Stahl RA. Linked common polymorphisms in the gelatinase a promoter are associated with diminished transcriptional response to estrogen and genetic fitness. J Biol Chem. 2003 Jun 06; 278(23):20490-9.

Bergman MR, Cheng S, Honbo N, Piacentini L, Karliner JS, Lovett DH. A functional activating protein 1 (AP-1) site regulates matrix metalloproteinase 2 (MMP-2) transcription by cardiac cells through interactions with JunB-Fra1 and JunB-FosB heterodimers. Biochem J. 2003 Feb 01; 369(Pt 3):485-96.

Pollock AS, Turck J, Lovett DH. The prodomain of interleukin 1alpha interacts with elements of the RNA processing apparatus and induces apoptosis in malignant cells. FASEB J. 2003 Feb; 17(2):203-13.

Cheng S, Alfonso-Jaume MA, Mertens PR, Lovett DH. Tumour metastasis suppressor, nm23-beta, inhibits gelatinase A transcription by interference with transactivator Y-box protein-1 (YB-1). Biochem J. 2002 Sep 15; 366(Pt 3):807-16.

Reisdorff J, En-Nia A, Stefanidis I, Floege J, Lovett DH, Mertens PR. Transcription factor Ets-1 regulates gelatinase a gene expression in mesangial cells. J Am Soc Nephrol. 2002 Jun; 13(6):1568-78.

Mertens PR, Steinmann K, Alfonso-Jaume MA, En-Nia A, Sun Y, Lovett DH. Combinatorial interactions of p53, activating protein-2, and YB-1 with a single enhancer element regulate gelatinase A expression in neoplastic cells. J Biol Chem. 2002 Jul 12; 277(28):24875-82.

Ikeda K, Wang LH, Torres R, Zhao H, Olaso E, Eng FJ, Labrador P, Klein R, Lovett D, Yancopoulos GD, Friedman SL, Lin HC. Discoidin domain receptor 2 interacts with Src and Shc following its activation by type I collagen. J Biol Chem. 2002 May 24; 277(21):19206-12.

Olaso E, Labrador JP, Wang L, Ikeda K, Eng FJ, Klein R, Lovett DH, Lin HC, Friedman SL. Discoidin domain receptor 2 regulates fibroblast proliferation and migration through the extracellular matrix in association with transcriptional activation of matrix metalloproteinase-2. J Biol Chem. 2002 Feb 01; 277(5):3606-13.

Harendza S, Lovett DH, Stahl RA. The hematopoietic transcription factor PU.1 represses gelatinase A transcription in glomerular mesangial cells. J Biol Chem. 2000 Jun 30; 275(26):19552-9.

Mahimkar RM, Baricos WH, Visaya O, Pollock AS, Lovett DH. Identification, cellular distribution and potential function of the metalloprotease-disintegrin MDC9 in the kidney. J Am Soc Nephrol. 2000 Apr; 11(4):595-603.

Mertens PR, Alfonso-Jaume MA, Steinmann K, Lovett DH. YB-1 regulation of the human and rat gelatinase A genes via similar enhancer elements. J Am Soc Nephrol. 1999 Dec; 10(12):2480-7.

Mertens PR, Alfonso-Jaume MA, Steinmann K, Lovett DH. A synergistic interaction of transcription factors AP2 and YB-1 regulates gelatinase A enhancer-dependent transcription. J Biol Chem. 1998 Dec 04; 273(49):32957-65.

Tanney DC, Feng L, Pollock AS, Lovett DH. Regulated expression of matrix metalloproteinases and TIMP in nephrogenesis. Dev Dyn. 1998 Sep; 213(1):121-9.

Mertens PR, Harendza S, Pollock AS, Lovett DH. Glomerular mesangial cell-specific transactivation of matrix metalloproteinase 2 transcription is mediated by YB-1. J Biol Chem. 1997 Sep 05; 272(36):22905-12.

Turck J, Pollock AS, Lovett DH. Gelatinase A is a glomerular mesangial cell growth and differentiation factor. Kidney Int. 1997 May; 51(5):1397-400.

Stevenson FT, Turck J, Locksley RM, Lovett DH. The N-terminal propiece of interleukin 1 alpha is a transforming nuclear oncoprotein. Proc Natl Acad Sci U S A. 1997 Jan 21; 94(2):508-13.

McMillan JI, Weeks R, West JW, Bursten S, Rice GC, Lovett DH. Pharmacological inhibition of gelatinase B induction and tumor cell invasion. Int J Cancer. 1996 Aug 07; 67(4):523-31.

Turck J, Pollock AS, Lee LK, Marti HP, Lovett DH. Matrix metalloproteinase 2 (gelatinase A) regulates glomerular mesangial cell proliferation and differentiation. J Biol Chem. 1996 Jun 21; 271(25):15074-83.

McMillan JI, Riordan JW, Couser WG, Pollock AS, Lovett DH. Characterization of a glomerular epithelial cell metalloproteinase as matrix metalloproteinase-9 with enhanced expression in a model of membranous nephropathy. J Clin Invest. 1996 Feb 15; 97(4):1094-101.

Harendza S, Pollock AS, Mertens PR, Lovett DH. Tissue-specific enhancer-promoter interactions regulate high level constitutive expression of matrix metalloproteinase 2 by glomerular mesangial cells. J Biol Chem. 1995 Aug 11; 270(32):18786-96.

Lee LK, Meyer TW, Pollock AS, Lovett DH. Endothelial cell injury initiates glomerular sclerosis in the rat remnant kidney. J Clin Invest. 1995 Aug; 96(2):953-64.

Lovett DH. Immunologic glomerular disease--new prospects for specific therapy. West J Med. 1994 May; 160(5):481-2.

Johnson RJ, Lovett D, Lehrer RI, Couser WG, Klebanoff SJ. Role of oxidants and proteases in glomerular injury. Kidney Int. 1994 Feb; 45(2):352-9.

Gaire M, Magbanua Z, McDonnell S, McNeil L, Lovett DH, Matrisian LM. Structure and expression of the human gene for the matrix metalloproteinase matrilysin. J Biol Chem. 1994 Jan 21; 269(3):2032-40.

Marti HP, Lee L, Kashgarian M, Lovett DH. Transforming growth factor-beta 1 stimulates glomerular mesangial cell synthesis of the 72-kd type IV collagenase. Am J Pathol. 1994 Jan; 144(1):82-94.

Johnson RJ, Lovett D. In vivo gene transfer, Koch's postulates, and renal disease. J Clin Invest. 1993 Dec; 92(6):2568.

Lee LK, Pollock AS, Lovett DH. Asymmetric origins of the mature glomerular basement membrane. J Cell Physiol. 1993 Oct; 157(1):169-77.

Stevenson FT, Bursten SL, Fanton C, Locksley RM, Lovett DH. The 31-kDa precursor of interleukin 1 alpha is myristoylated on specific lysines within the 16-kDa N-terminal propiece. Proc Natl Acad Sci U S A. 1993 Aug 01; 90(15):7245-9.

Marti HP, McNeil L, Davies M, Martin J, Lovett DH. Homology cloning of rat 72 kDa type IV collagenase: cytokine and second-messenger inducibility in glomerular mesangial cells. Biochem J. 1993 Apr 15; 291 ( Pt 2):441-6.

Marti HP, Lovett DH. [Current aspects in the pathogenesis and therapy of glomerulonephritis: significance of glomerular metalloproteinases]. Schweiz Med Wochenschr. 1992 Nov 07; 122(45):1701-7.

Stevenson FT, Bursten SL, Locksley RM, Lovett DH. Myristyl acylation of the tumor necrosis factor alpha precursor on specific lysine residues. J Exp Med. 1992 Oct 01; 176(4):1053-62.

Stevenson FT, Torrano F, Locksley RM, Lovett DH. Interleukin 1: the patterns of translation and intracellular distribution support alternative secretory mechanisms. J Cell Physiol. 1992 Aug; 152(2):223-31.

Marti HP, McNeil L, Thomas G, Davies M, Lovett DH. Molecular characterization of a low-molecular-mass matrix metalloproteinase secreted by glomerular mesangial cells as PUMP-1. Biochem J. 1992 Aug 01; 285 ( Pt 3):899-905.

Lovett DH, Johnson RJ, Marti HP, Martin J, Davies M, Couser WG. Structural characterization of the mesangial cell type IV collagenase and enhanced expression in a model of immune complex-mediated glomerulonephritis. Am J Pathol. 1992 Jul; 141(1):85-98.

Pollock AS, Lovett DH. Expression of phosphoenolpyruvate carboxykinase (PEPCK) chimeras in renal epithelial cells. Retention of appropriate physiological responsiveness using enhancerless retroviral vectors. Biochem J. 1992 Jun 15; 284 ( Pt 3):725-32.

Johnson R, Yamabe H, Chen YP, Campbell C, Gordon K, Baker P, Lovett D, Couser WG. Glomerular epithelial cells secrete a glomerular basement membrane-degrading metalloproteinase. J Am Soc Nephrol. 1992 Mar; 2(9):1388-97.

Davies M, Martin J, Thomas GJ, Lovett DH. Proteinases and glomerular matrix turnover. Kidney Int. 1992 Mar; 41(3):671-8.

Bursten SL, Harris WE, Resch K, Lovett DH. Lipid A activation of glomerular mesangial cells: mimicry of the bioactive lipid, phosphatidic acid. Am J Physiol. 1992 Feb; 262(2 Pt 1):C328-38.

Bursten SL, Harris WE, Bomsztyk K, Lovett D. Interleukin-1 rapidly stimulates lysophosphatidate acyltransferase and phosphatidate phosphohydrolase activities in human mesangial cells. J Biol Chem. 1991 Nov 05; 266(31):20732-43.

Bursten SL, Stevenson F, Torrano F, Lovett DH. Mesangial cell activation by bacterial endotoxin. Induction of rapid cytoskeletal reorganization and gene expression. Am J Pathol. 1991 Aug; 139(2):371-82.

Davies M, Coles GA, Thomas GJ, Martin J, Lovett DH. Proteinases and the glomerulus: their role in glomerular diseases. Klin Wochenschr. 1990 Nov 16; 68(22):1145-9.

Bommer J, Weinreich T, Lovett DH, Bouillon R, Ritz E, Gemsa D. Particles from dialysis tubing stimulate interleukin-1 secretion by macrophages. Nephrol Dial Transplant. 1990; 5(3):208-13.

Martin J, Davies M, Thomas G, Lovett DH. Human mesangial cells secrete a GBM-degrading neutral proteinase and a specific inhibitor. Kidney Int. 1989 Nov; 36(5):790-801.

Martin M, Lovett DH, Szamel M, Resch K. Characterization of the interleukin-1-induced tyrosine phosphorylation of a 41-kDa plasma membrane protein of the human tumor cell line K 562. Eur J Biochem. 1989 Mar 15; 180(2):343-50.

Lovett DH, Bursten SL, Gemsa D, Bessler W, Resch K, Ryan JL. Activation of glomerular mesangial cells by gram-negative bacterial cell wall components. Am J Pathol. 1988 Dec; 133(3):472-84.

Person JM, Lovett DH, Raugi GJ. Modulation of mesangial cell migration by extracellular matrix components. Inhibition by heparinlike glycosaminoglycans. Am J Pathol. 1988 Dec; 133(3):609-14.

Bursten SL, Locksley RM, Ryan JL, Lovett DH. Acylation of monocyte and glomerular mesangial cell proteins. Myristyl acylation of the interleukin 1 precursors. J Clin Invest. 1988 Nov; 82(5):1479-88.

Abrass CK, Raugi GJ, Gabourel LS, Lovett DH. Insulin and insulin-like growth factor I binding to cultured rat glomerular mesangial cells. Endocrinology. 1988 Nov; 123(5):2432-9.

Lovett DH, Martin M, Bursten S, Szamel M, Gemsa D, Resch K. Interleukin 1 and the glomerular mesangium. III. IL-1-dependent stimulation of mesangial cell protein kinase activity. Kidney Int. 1988 Jul; 34(1):26-35.

Lovett DH, Larsen A. Cell cycle-dependent interleukin 1 gene expression by cultured glomerular mesangial cells. J Clin Invest. 1988 Jul; 82(1):115-22.

Davies M, Thomas GJ, Martin J, Lovett DH. The purification and characterization of a glomerular-basement-membrane-degrading neutral proteinase from rat mesangial cells. Biochem J. 1988 Apr 15; 251(2):419-25.

Lovett DH, Resch K, Gemsa D. Interleukin I and the glomerular mesangium. II. Monokine stimulation of mesangial cell prostanoid secretion. Am J Pathol. 1987 Dec; 129(3):543-51.

Raugi GJ, Lovett DH. Thrombospondin secretion by cultured human glomerular mesangial cells. Am J Pathol. 1987 Nov; 129(2):364-72.

Lovett DH, Haensch GM, Goppelt M, Resch K, Gemsa D. Activation of glomerular mesangial cells by the terminal membrane attack complex of complement. J Immunol. 1987 Apr 15; 138(8):2473-80.

Sterzel RB, Lovett DH, Foellmer HG, Perfetto M, Biemesderfer D, Kashgarian M. Mesangial cell hillocks. Nodular foci of exaggerated growth of cells and matrix in prolonged culture. Am J Pathol. 1986 Oct; 125(1):130-40.

Resch K, Martin M, Lovett DH, Kyas U, Gemsa D. The receptor for interleukin 1 in plasma membranes of the human leukemia cell K 562: biological and biochemical characterization. Immunobiology. 1986 Sep; 172(3-5):336-45.

Lovett DH, Sterzel RB. Cell culture approaches to the analysis of glomerular inflammation. Kidney Int. 1986 Aug; 30(2):246-54.

Martin J, Lovett DH, Gemsa D, Sterzel RB, Davies M. Enhancement of glomerular mesangial cell neutral proteinase secretion by macrophages: role of interleukin 1. J Immunol. 1986 Jul 15; 137(2):525-9.

Lovett DH, Szamel M, Ryan JL, Sterzel RB, Gemsa D, Resch K. Interleukin 1 and the glomerular mesangium. I. Purification and characterization of a mesangial cell-derived autogrowth factor. J Immunol. 1986 May 15; 136(10):3700-5.

Martin M, Lovett D, Resch K. Interleukin 1 induces specific phosphorylation of a 41 kDa plasma membrane protein from the human tumor cell line K 562. Immunobiology. 1986 Apr; 171(3):165-9.

Lovett D, Kozan B, Hadam M, Resch K, Gemsa D. Macrophage cytotoxicity: interleukin 1 as a mediator of tumor cytostasis. J Immunol. 1986 Jan; 136(1):340-7.

Resch K, Martin M, Lovett DH, Gemsa D. Measurement of interleukin-1 by growth inhibition of the human tumor cell K562; receptor studies. Lymphokine Res. 1986; 5 Suppl 1:S81-6.

Lovett DH, Sterzel RB, Ryan JL, Atkins E. Production of an endogenous pyrogen by glomerular mesangial cells. J Immunol. 1985 Feb; 134(2):670-2.

Stoeck M, Wildhagen K, Szamel M, Lovett D, Resch K. Studies on the mechanism whereby cyclosporin A inhibits T-lymphocyte activation. Immunobiology. 1985 Feb; 169(1):83-96.

Lovett DH, Ryan JL, Sterzel RB. Stimulation of rat mesangial cell proliferation by macrophage interleukin 1. J Immunol. 1983 Dec; 131(6):2830-6.

Lovett DH, Ryan JL, Sterzel RB. A thymocyte-activating factor derived from glomerular mesangial cells. J Immunol. 1983 Apr; 130(4):1796-801.

Lovett DH, Sterzel RB, Kashgarian M, Ryan JL. Neutral proteinase activity produced in vitro by cells of the glomerular mesangium. Kidney Int. 1983 Feb; 23(2):342-9.

Sterzel RB, Lovett DH, Stein HD, Kashgarian M. The mesangium and glomerulonephritis. Klin Wochenschr. 1982 Sep 15; 60(18):1077-94.

Lovett DH, Ryan JL, Kashgarian M, Sterzel RB. Lysosomal enzymes in glomerular cells of the rat. Am J Pathol. 1982 May; 107(2):161-6.

Mazur EM, Lovett DH, Enriquez RE, Breg WR, Papac RJ. Angioimmunoblastic lymphadenopathy evolution to a Burkitt-like lymphoma. Am J Med. 1979 Aug; 67(2):317-24.

  Select data provided by UCSF Profiles, powered by CTSI at UCSF. Learn more about the data source.